A detailed history of Spire Wealth Management transactions in Macrogenics Inc stock. As of the latest transaction made, Spire Wealth Management holds 664 shares of MGNX stock, worth $2,177. This represents 0.0% of its overall portfolio holdings.

Number of Shares
664
Previous 664 -0.0%
Holding current value
$2,177
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$9.77 - $21.47 $488 - $1,073
50 Added 8.14%
664 $9,000
Q4 2023

Feb 06, 2024

SELL
$4.48 - $10.11 $2,240 - $5,055
-500 Reduced 44.88%
614 $5,000
Q3 2023

Nov 08, 2023

BUY
$4.48 - $6.19 $4,990 - $6,895
1,114 New
1,114 $5,000
Q2 2022

Jul 22, 2022

SELL
$2.25 - $9.99 $270 - $1,198
-120 Closed
0 $0
Q2 2021

Jul 26, 2021

SELL
$20.49 - $35.63 $30,734 - $53,445
-1,500 Reduced 92.59%
120 $3,000
Q1 2021

May 21, 2021

BUY
$18.99 - $33.2 $30,763 - $53,784
1,620 New
1,620 $52,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $202M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.